(Q47653459)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

title

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

11

Vernon K Sondak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1

Sarah Sloot

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

12

Geoffrey T Gibney

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

10

Peter A Forsyth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

9

Jonathan S Zager

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

2

Yian A Chen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

6

James J Mulé

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

author name string

Xiuhua Zhao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Jamie L Weber

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Jacob J Benedict

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Jeffrey S Weber

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

language of work or name

English

0 references

publication date

12 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

volume

124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

page(s)

297-305

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29023643%20AND%20SRC:MED&resulttype=core&format=json

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

7 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Diagnosis and treatment of melanoma brain metastasis: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Determinants of outcome in melanoma patients with cerebral metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

The role of the organ microenvironment in brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Melanoma in the brain: biology and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

The anatomical and cellular basis of immune surveillance in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Vemurafenib and radiation therapy in melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Ipilimumab and radiation therapy for melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

Prognostic factors for survival in melanoma patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30946

inferred from DOI database lookup

7 January 2021

based on heuristic

Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29023643